Investigating the role of FoxO1 in gestational diabetes
FoxO1 in Gestational Diabetes
This study is looking at how the body’s insulin-producing cells change during pregnancy to help women who are at risk for gestational diabetes, with the goal of finding better ways to diagnose and treat this condition for healthier moms and babies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10843834 on NIH RePORTER |
What this research studies
This research focuses on understanding gestational diabetes mellitus (GDM), a condition that affects pregnant women and can lead to serious health issues for both mother and baby. The study aims to explore how pancreatic beta cells adapt to insulin resistance during pregnancy and what causes their failure in women at risk for GDM. By examining the role of the FoxO1 transcription factor, the research seeks to uncover the mechanisms behind beta-cell compensation and insulin regulation in pregnant women. This could lead to better diagnostic and therapeutic strategies for managing GDM.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women, particularly those at risk for developing gestational diabetes.
Not a fit: Patients who are not pregnant or those who have a history of diabetes prior to pregnancy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management and treatment options for gestational diabetes, enhancing the health outcomes for mothers and their babies.
How similar studies have performed: Previous research has shown promising results in understanding insulin resistance and beta-cell function during pregnancy, indicating that this approach has potential for success.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Dong, Hengjiang Henry — University of Pittsburgh at Pittsburgh
- Study coordinator: Dong, Hengjiang Henry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.